scAAV1.tMCK.NTF3

N/A

Report date: 2023/10/26 16:47:11

Base Information

Drug NamescAAV1.tMCK.NTF3
Drug Alias NameAAV1.NT-3 gene therapyrAAV1.NT-3 gene therapyNeurotrophin-3 gene therapyscAAV1.tMCK.NTF3 (Nationwide Children's Hospital/Sarepta Therapeutics)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV1 vector
Mechanisms of ActionNeurotrophin-3 expression stimulantsGene transference
TargetsNeurotrophin-3
Therapy Area/IndicationsCharcot-Marie-Tooth Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNationwide Children'S HospitalSarepta Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesNationwide Children'S Hospital
Inactive CompaniesN/A
Active IndicationsCharcot-Marie-Tooth Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A